Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caelyx as Adjuvant Treatment in Early Stage Luminal B Breast Cancer (Feasibility Phase II)
2014-000842-30Phase 2Completed
- Sponsor
- European Institute of Oncology
- Start
- Jan 2021
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegylated liposomal doxorubicin in Luminal B breast cancer and breast cancer, sponsored by European Institute of Oncology. Primary endpoint: Feasibility of adjuvant PLD (Caelyx). Started Jan 2021; status: completed.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
Luminal B breast cancerbreast cancer
Beyond the preview
Go deeper on 2014-000842-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000842-30.